FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Sodium-glucose cotransporter 2 inhibitors in horses-Magic bu...
Equine veterinary journal2023; 55(4); 559-562; doi: 10.1111/evj.13944

Sodium-glucose cotransporter 2 inhibitors in horses-Magic bullet or latest fad?

Abstract: No abstract available
Get Full Text
Publication Date: 2023-05-15 PubMed ID: 37190880DOI: 10.1111/evj.13944Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Editorial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study focuses on the application and effectiveness of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) in treating hyperinsulinaemia-associated laminitis (HAL) in horses.

Introduction and Background

  • SGLT2 inhibitors like Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin, widely used as human antidiabetic medications, primarily work to lower insulin concentration, promote weight loss, and reduce blood pressure.
  • These drugs block the absorption of glucose in the kidneys, thus promoting urinary glucose excretion, lowering plasma glucose levels, and reducing the insulin secretion stimulus from the pancreas.
  • This study examines their use in equine practice as the drugs are increasingly being used today as prevention and treatment of hyperinsulinaemia-associated laminitis in horses with equine metabolic syndrome.

Challenges and Concerns

  • The research highlights the need for caution when extrapolating findings from one species to another due to unique biological variations.
  • The challenge in managing laminitis, majorly caused by high insulin concentration, is further complicated by horse owners’ hesitation to limit access to pasture or forage on their horse-human bond’s grounds, leading to poor compliance with veterinary recommendations.
  • There’s a pressing need for safe and effective treatments for HAL as the condition, largely preventable, leads to unacceptable levels of morbidity and mortality.

Results and Potential Outcomes

  • Experimental studies have demonstrated that drugs like velagliflozin can help lower insulin concentrations and prevent laminitis development in horses with high non-structural carbohydrate diets.
  • In a retrospective case study of 51 horses with HAL, administration of ertugliflozin for 30 days resulted in a significant reduction in insulin concentration and noticeable improvement in laminitis-associated lameness, and it allowed stopping non-steroidal anti-inflammatory (NSAID) treatment in almost all cases within 2 weeks.
  • Similarly, canagliflozin showed promising results with reduced insulin concentration and resolution of lameness in horses suffering from refractory hyperinsulinaemia and laminitis.

Use in Managing Equine Obesity

  • SGLT2i may also prove valuable in managing equine obesity where diet adjustment alone has proved inadequate.
  • Horses treated with ertugliflozin revealed significant weight loss after 30 days, with a median reduction of 6% body weight over the period.
  • However, pharmaceuticals should not be considered a substitute for dietary management, and horse owners should always maintain dietary restrictions when using SGLT2i.

The study recognizes the limits of the research, including the absence of control groups, small sample sizes, and reliance on retrospective data. Despite these constraints, the article points to the potentially transformative impact of SGLT2i in treating laminitis and obesity in horses.

Cite This Article

APA
Sundra T, Lester G, Rossi G, Rendle D. (2023). Sodium-glucose cotransporter 2 inhibitors in horses-Magic bullet or latest fad? Equine Vet J, 55(4), 559-562. https://doi.org/10.1111/evj.13944

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 55
Issue: 4
Pages: 559-562

Researcher Affiliations

Sundra, Tania
  • Avon Ridge Equine Veterinary Services, Brigadoon, Western Australia, Australia.
Lester, Guy
  • Equiimed, Perth, Western Australia, Australia.
Rossi, Gabriele
  • School of Veterinary and Biomedical Sciences, Murdoch University, Murdoch, Western Australia, Australia.
Rendle, David
  • EMT Consulting, Tiverton, Devon, UK.

MeSH Terms

  • Horses
  • Animals
  • Hyperinsulinism / veterinary
  • Insulin Resistance
  • Glucose
  • Sodium
  • Horse Diseases / drug therapy
  • Foot Diseases / veterinary
  • Insulin
  • Inflammation / veterinary

References

This article includes 52 references
  1. Kalra S, Singh V, Nagrale D. Sodium-glucose cotransporter-2 inhibition and the glomerulus: a review.. Adv Ther 2016;33(9):1502-18.
  2. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.. Drug des Dev Ther 2014;8:1335-80.
  3. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.. N Engl J Med 2016;374(11):1092-4.
  4. Neal B, Perkovic V, Mahaffey KW, Zeeuw D d, Fulcher G, Erondu N. Canagliflozin and cardiovascular and renal events in type 2 diabetes.. N Engl J Med 2017;377(7):644-57.
  5. Wiviott SD, Raz I, Sabatine MS. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.. N Engl J Med 2019;380(19):1880-1.
  6. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M. Empagliflozin and progression of kidney disease in type 2 diabetes.. N Engl J Med 2016;375(4):323-34.
  7. Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.. Diabetologia 2018;61(10):2098-107.
  8. Zheng H, Liu M, Li S, Shi Q, Zhang S, Zhou Y. Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis.. Front Endocrinol 2021;12:706914.
  9. Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents.. Metabolism 2022;127:154937.
  10. Fediuk DJ, Nucci G, Dawra VK, Cutler DL, Amin NB, Terra SG. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor.. Clin Pharmacokinet 2020;59(8):949-65.
  11. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.. Diabet Med 2010;27(2):136-42.
  12. Meier A, de Laat M, Reiche D, Fitzgerald D, Sillence M. The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies.. BMC Vet Res 2019;15(1):65.
  13. Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.. Plos One 2018;13(9):e0203655.
  14. Sundra T, Kelty E, Rendle D. Preliminary observations on the use of ertugliflozin in the management of hyperinsulinaemia and laminitis in 51 horses: a case series.. Equine Vet Educ 2022;35(6):311-320.
    doi: 10.1111/eve.13738google scholar: lookup
  15. Kellon EM, Gustafson KM. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.. Open Vet J 2022;12(4):511-8.
  16. Thane K, Voth R, Klee R, Warnken T, Frank N. The sodium-glucose cotransporter-2 inhibitor velagliflozin decreases basal plasma insulin concentrations in horses with moderate-severe insulin dysregulation.. In: 5th global equine endocrine symposium. Bern, Switzerland; 2023. [cited 2023 May 10]. Available from: https://sites.tufts.edu/equineendogroup/files/2020/01/GEES_2020_Proceedings.pdf.
  17. Ireland JL, Clegg PD, McGowan CM, Platt L, Pinchbeck GL. Factors associated with mortality of geriatric horses in the United Kingdom.. Prev Vet Med 2011;101(3-4):204-18.
  18. Bamford NJ, Potter SJ, Baskerville CL, Harris PA, Bailey SR. Influence of dietary restriction and low-intensity exercise on weight loss and insulin sensitivity in obese equids.. J Vet Intern Med 2019;33(1):280-6.
  19. Furtado T, Perkins E, Pinchbeck G, McGowan C, Watkins F, Christley R. Exploring horse owners' understanding of obese body condition and weight management in UK leisure horses.. Equine Vet J 2021;53(4):752-62.
  20. Knowles EJ, Elliott J, Harris PA, Chang Y, Menzies-Gow NJ. Predictors of laminitis development in a cohort of nonlaminitic ponies.. Equine Vet J 2023;55(1):12-23.
  21. Owers R, Chubbock S. Fight the fat!. Equine Vet J 2013;45(1):5.
  22. Menzies-Gow NJ, Harris PA, Elliott J. Prospective cohort study evaluating risk factors for the development of pasture-associated laminitis in the United Kingdom.. Equine Vet J 2017;49(3):300-6.
  23. Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).. Diabetes Obes Metab 2018;20(3):520-9.
  24. Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.. Obesity 2014;22(4):1042-9.
  25. Janež A, Fioretto P. SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: a narrative review.. Diabetes Ther 2021;12(8):2249-2261.
  26. Rosenstock J, Jelaska A, Wang F, Kim G, Broedl U, Woerle HJ. Empagliflozin as add on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM).. Can J Diabetes 2013;37:S32.
  27. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology.. Diabetes Ther 2014;5(2):355-66.
  28. Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.. Diabetes Obes Metab 2014;16(2):159-69.
  29. Prato SD, Nauck M, Durán-Garcia S, Maffei L, Rohwedder K, Theuerkauf A. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.. Diabetes Obes Metab 2015;17(6):581-90.
  30. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity.. Drugs 2019;79(3):219-30.
  31. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy balance after sodium-glucose cotransporter 2 inhibition.. Diabetes Care 2015;38(9):1730-5.
  32. Agcakaya E, Mutlu HH, Erbakan A, Sargin M. Comparison of the impact of SGLT2-inhibitors and exenatide on body fat composition.. J Coll Physicians Surg Pak 2023;33(3):308-13.
  33. Al-Ozairi E, Irshad M, Taghadom E, Sojan L, Kandari JA, Alroudhan D. Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.. Obesity 2023;31(3):716-23.
  34. Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism.. Metabolites 2021;11(2):87.
  35. Benedict SL, Mahony OM, McKee TS, Bergman PJ. Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.. Can J Vet Res 2021;86(1):52-8.
  36. Sargent J. SGLT2 inhibitor dapagliflozin promotes glucagon secretion in [alpha] islet cells.. Nat Rev Endocrinol 2015;11(7):382-2.
  37. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.. J Clin Invest 2014;124(2):499-508.
  38. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes.. Diabetes 2016;65(5):1190-5.
  39. Dunkel B, Wilford SA, Parkinson NJ, Ward C, Smith P, Grahame L. Severe hypertriglyceridaemia in horses and ponies with endocrine disorders.. Equine Vet J 2014;46(1):118-22.
  40. Kellon EM, Gustafson KM. Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.. Open Vet J 2023;13(3):365-75.
  41. Thiruvenkatarajan V, Jesudason D, Nanjappa N, Meyer EJ, Wijk RMV. Perioperative Management of Glucose-lowering Drugs: comment.. Anesthesiology 2021;134(2):349-50.
  42. Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.. Nat Rev Nephrol 2021;17(1):65-77.
  43. Aziri B, Begic E, Jankovic S, Mladenovic Z, Stanetic B, Kovacevic-Preradovic T. Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events.. Esc Heart Fail 2023.
  44. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.. J Pharmacol Sci 2016;130(3):159-69.
  45. Suzuki Y, Kaneko H, Okada A, Itoh H, Matsuoka S, Fujiu K. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus.. Cardiovasc Diabetol 2022;21(1):67.
  46. Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.. Expert Opin Inv Drug 2013;22(4):463-86.
  47. Wilding J. SGLT2 inhibitors and urinary tract infections.. Nat Rev Endocrinol 2019;15(12):687-8.
  48. List J, Whaley J. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.. Kidney Int 2011;79(S120):20-7.
  49. Mosley JF, Smith L, Everton E, Fellner C. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview.. P T 2015;40(7):451-62.
  50. Grünert SC, Rosenbaum-Fabian S, Schumann A, Selbitz A, Merz W, Gieselmann A. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib.. JIMD Rep 2022;63(4):303-8.
  51. Glueck CJ, Goldenberg N, Streicher P, Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.. Expert Opin Pharmacother 2002;3(11):1557-68.
  52. Fowden A, Comline R, Silver M. Insulin secretion and carbohydrate metabolism during pregnancy in the mare.. Equine Vet J 1984;16(4):239-46.

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.